Introduction
For patients with aggressive lymphomas, the clinical prognosis for T-cell phenotype is poor in comparison to B-cell phenotype, with the notable exception of ALK þ anaplastic large cell lymphoma. 1 Mature T-cell lymphomas comprise only B7% of all non-Hodgkin's lymphoma (NHL) worldwide and include peripheral T-cell lymphoma not-otherwise specified, cutaneous T-cell lymphoma (CTCL), angioimmunoblastic lymphoma, anaplastic large-cell lymphoma and natural killer T-cell neoplasms among others. 2, 3 Advanced disease stage, poor prognostic factors at presentation 4 and inherent chemoresistance play a part in the dismal outcomes. 5 The treatment of CTCL represents additional challenges due to the often protracted, debilitating disease course and the absence of a standard of care. 6 Current therapeutic strategies for mature T-cell lymphomas are poorly defined and are associated with a high rate of chemorefractory disease and relapse following chemotherapy, both with and without autologous stem cell rescue. As a result, disease progression remains a significant clinical dilemma in the care of these patients.
In response to this often incurable disease course, we have offered allogeneic (related or matched unrelated) haematopoietic cell transplantation (allo-HCT) to mature T-cell lymphoma patients as salvage therapy, in an attempt to harness a potential GVL effect. [7] [8] [9] [10] [11] [12] [13] Allo-HCT is a potentially curative option, but is associated with high nonrelapse mortality (NRM). It is now well established that reduced-intensity transplant conditioning (RIC) regimens confer the benefits of the graft-vs-malignancy effect, with efficacies similar to myeloablative conditioning for the treatment of some haematological malignancies, 14, 15 including NHL. 13, 16, 17 Although RIC regimens have lower intensity and toxicity, they are available to older and more heavily pre-treated patients without increasing NRM; however, their effectiveness varies for different diseases.
Here we report the retrospective analysis of patients with mature T-cell lymphomas who received salvage therapy using allo-HCT, with a standardized reduced-intensity fludarabine/melphalan conditioning regimen at the City of Hope between 2001 and 2008.
Patients and methods

Inclusion criteria
Following approval by the Institutional Review Board, a query of the City of Hope transplant database identified a consecutive case series of 27 patients with mature T-cell lymphomas treated with allo-HCT (HLA-matched sibling or matched unrelated donor) between 2001 and 2008 using a standardized reduced-intensity fludarabine/melphalan conditioning regimen. Allo-HCT was offered to the patients with refractory or relapsed disease who were not candidates for autologous HCT due to chemo-refractory/ progressive disease, extensive BM involvement or failure to adequately mobilize stem cells. 18, 19 Patients with CTCL were not considered candidates for autologous HCT because of the disappointing outcomes with this approach. 20, 21 As per institutional practice, all patients were evaluated pretransplant for organ function of heart, lungs and kidneys. Donor selection was based on the availability of an HLA-identical family donor, or alternatively from an HLA-matched unrelated donor based on molecular typing of HLA A, B, C, DR and DQ loci.
Treatment regimen
All patients underwent RIC with fludarabine 25 mg/m 2 i.v. daily on days À9 through À5 and melphalan 140 mg/m 2 i.v. on day À4 before the infusion of BM (11%) or PBSCs (89%). In all, 56% of patients received stem cells from HLA-matched siblings, and 44% from matched unrelated donors. A total of 18 patients (67%) received GVHD prophylaxis with sirolimus/tacrolimus, whereas nine patients (33%) received cyclosporine/mycophenolate mofetil (MMF)-based prophylaxis. GVHD prophylaxis was decided as per the discretion of treating physicians on the basis of institutional protocols, donor type and product source (prophylaxis for individual patients is listed in Table 1 ).
Patient characteristics
Summary patient characteristics are listed in Table 1 , with individual patient details displayed in Table 2 . Mature T-cell lymphoma histologies included peripheral T-cell lymphoma not otherwise specified (n ¼ 5); angioimmunoblastic T cell lymphomas (n ¼ 3); anaplastic large-cell lymphomas (n ¼ 2; both ALK þ ); rare histologies (n ¼ 6, natural killer T-cell nasal and extranasal, s.c. panniculitislike); and CTCL(n ¼ 11, mycosis fungoides and Sezary syndrome). Most patients (n ¼ 17, 63%) had advanced disease at the time of transplant: relapse, induction failure or primary refractory disease. The rest of the patients were in CR (CR1 ¼ 1, CR2 ¼ 5) and partial response (PR ¼ 4). Among CTCL patients, only one was in CR following six different treatment regimens, and another was in PR after four earlier regimens. The median age was 50 years (range: 19-68) and 74% of the patients were male (n ¼ 20). The median time from diagnosis to transplant for the majority of the patients was greater than 1 year: for CTCL it was 28.8 months (range 17.2-4.2); for other subtypes it was 12.6 months (range 6.2 -112.3). The median number of earlier regimens was 4 (range: 1-9) for all patients, 6 (range [4] [5] [6] [7] [8] [9] for patients with CTCL and 3 (range 1-8) for other patients. Only one patient had undergone earlier autologous transplant. RIC HCT for T-cell lymphoma M Delioukina et al Statistics Survival estimates were calculated on the basis of the product-limit method, and 95% confidence intervals were calculated using the logit transformation and the Greenwood variance estimate. 22 Differences between survival curves were assessed by the log rank test. OS was measured from stem cell infusion to death from any cause. PFS was defined as time from stem cell infusion to recurrence, progression or death from any cause, whichever occurred first. The cumulative incidence of relapse/progression rate was defined as time from stem cell infusion to recurrence or progression. NRM (cumulative incidence) was measured from stem cell infusion to death from any cause other than disease relapse or disease progression. Cumulative relapse/ progression incidence was calculated by controlling for non-relapse-related death as a competing risk and, conversely, NRM was calculated by controlling for relapse/ progression as a competing risk. 23 Differences between survival curves were assessed by log-rank or Gray's test 24 as appropriate. The significance of demographic/treatment features collected on HCT recipients was assessed by the log rank test, and univariate/multivariable Cox regression analysis 25 or the corresponding hazard analysis for competing risks. 26 Generally statistical significance was defined at the Pp0.05 level. As part of the multivariable Cox regression analysis, factors shown to be significant at the 0.10 level in the univariate analysis were eligible for inclusion. Analysis of factors known to be associated with survival and disease outcomes included histopathological subtype (CTCL vs other histologies), patient age (younger or older than 50 years), disease status at the time of allo-HCT (CR/PR vs relapse/progression/induction failure), donor type (sibling vs matched unrelated), acute GVHD (aGVHD, grade (0-II vs III-IV)), chronic GVHD (cGVHD, none vs present and none/limited vs extensive) and GVHD prophylaxis (sirolimus-based vs other). All analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) and/or R 2.11.1 (http:// www.r-project.org).
Results
The median follow-up for the 13 (48%) surviving patients was 35.7 months (range:
Survival outcomes
There were a total of 14 deaths: five from disease progression/relapse and nine from non-relapse causes. Non-relapse causes (n ¼ 9) included infections (bacterial sepsis, pneumonias due to bacteria, respiratory syncytial virus and influenza A, cytomegalovirus infections) and GVHD-related complications. Day 100 mortality was 22% (n ¼ 6). The 2-year probability of OS was 55% (95% CI: 44-64%) and PFS was 47% (95% CI: 38-56%), as seen in 15-50%) and 22% (95% CI: 10-42%), respectively (curves shown in Figures 1c and d) .
When patients were stratified by histology, as seen in Figure 2 , the 2-year OS for CTCL was 45% (95% CI: 32-58%) compared with 62% (95% CI: 45-75%) for the other patients (P ¼ 0.38), with a PFS of 45% (95% CI: 32-58%) for CTCL and 49% (95% CI: 36-61%) for others (P ¼ 0.73). Relapse/progression was similar for both groups with CTCL, showing a 2-year cumulative incidence of 27% (95% CI: 8-61%) vs 31 (95% CI: 13-58%) for noncutaneous histologies. Non-relapse mortality at 2 years was 27% (95%CI: 8-60%) for the CTCL patients, compared with 19% (95% CI: 6-46%) for the other patients.
Among this high-risk patient population, relapse/progression and progression-related death events occurred in the first 1.5 years posttransplant; after that no events have been observed this far. Two of eight patients who progressed shortly after transplant received additional treatment and remained alive for 5 and 7 years, respectively, after transplant; both patients had modification of immunosuppression that resulted in extensive cGVHD. None of the patients received donor lymphocyte infusion during the post-transplant course.
Univariate/multivariable analyses Univariate and multivariable results for PFS are shown in Table 3 . Log-rank and Cox regression univariate analyses assessed factors known to be associated with survival and disease outcomes: age at transplant, histopathological subtype, disease status at transplant, donor type, GVHD prophylaxis, presence and grade of GVHD. Patients who were older (X50 years) at the time of transplant, and also those who developed little to no aGVHD (grade 0-II) had significantly improved OS and PFS. There was no statistically significant impact on PFS, OS, RPR or NRM on the basis of histopathological subtype (CTCL vs other subtypes), donor type (matched unrelated donor vs sibling donor), type of GHVD prophylaxis (CsA/MMF vs sirolimus/tacrolimus combinations), presence of cGVHD (none or none/limited vs extensive), or disease status at the time of transplant. All factors found to be significant at the Pp0.1 level in the univariate analysis were analyzed using multivariable Cox regression analysis. The results of this analysis showed that both younger age and the presence of aGVHD (grade III/IV) were significantly and independently associated with an increase in PFS hazard risk.
Discussion
It has been difficult to rigorously determine whether RIC allo-HCT is the optimal treatment for advanced haematological diseases, because of a lack of large randomized trials. Assessing RIC for mature T-cell lymphomas, and CTCL in particular, has the additional impediment of the rarity of the diagnosis and the limited data on allo-HCT for these diseases in general. Two European multi-center retrospective studies of allo-HCT (both myeloablative and RIC) for aggressive T-cell lymphoma 7 and for angioimmunoblastic T-cell lymphoma, 27 respectively, reported a 3-year OS of 57 and 64% and a 1-year NRM of 30 and 25%. Neither study reported a significant difference between RIC and myeloablative regimens in outcomes. Rodriguez et al. the two regimens, even in the small T-NHL subgroup.
In that study, the RIC group was at higher risk because of older median age, a higher proportion of previous autologous transplants and a higher percentage of unrelated donors in that group. Corradini et al., 10 in a prospective phase II trial, treated 17 peripheral T-cell lymphoma patients with a fludarabine, thiotepa and CR RIC regimen, and reported an impressive 3-year OS of 81%, PFS of 60% and a 1-year NRM of 6%; it is notable that 15 of these 17 patients were chemosensitive. In an expansion and update of this Corradini data set, reported in a review by Gutierrez et al., 13 for a population of 35 that included chemorefractory patients, the OS/PFS declined to 54/49%, with chemorefractory patient PFS at 25% compared with 72% for those transplanted in CR. There is some evidence that the prognostic differences between B-cell and T-cell histologies may be abrogated following treatment by allogeneic transplant; studies by both Rodriguez and Corradini 9, 16 observed similar survival and relapse rates for the B-and T-NHL phenotypes after RIC allo-HCT.
The literature on allogeneic transplant for CTCL is sparse; until recently, only case reports and small series have been published, including an eight-patient series from City of Hope. 28 A recent retrospective analysis of 60 CTCL patients from the European Journal for Blood and Marrow Transplantation registry 29 provides new insight into the role of allo-HCT for this rare disease. Duarte et al. 29 estimate an OS of 54% at 3 years, and show that use of RIC decreases the relative risk for NRM without increasing the relapse rate, resulting in a significantly higher OS. The major caveat of this report is the extensive use of T-cell depletion (42%) associated with a reduced PFS.
Here we report the results of a retrospective analysis of 27 patients treated with fludarabine/melphalan RIC alloHCT. The choice of fludarabine/melphalan regimen was based on the hypothesis that these agents have a substantial anti-lymphoma effect and can provide sufficient disease control while the GVL becomes established. Our data showed a 2-year OS of 55%, PFS of 47%, relapse/progression rate of 29% and NRM of 25%. Survival curves in this population appear to plateau after 24 months. Taking into consideration that 13 of 27 patients were induction failures, these results are encouraging.
As 41% of the patients in our report had the diagnosis of CTCL, representing a distinctive patient subgroup, we sought to evaluate the potential differences between this and other mature T-cell lymphoma histological subtypes. CTCL is characterized by a protracted disease course marked by transient responses to systemic treatment, followed by an inevitable recurrence. Patients are in an immunosuppressed state for years, because of both disease persistence and multiple lines of treatment, leading in many cases to death from infections and complications. CTCL remains an incurable disease and patients with advancedstage disease have a median survival of between 1.5-4 years from the time of diagnosis. 30, 31 This pattern is reflected in our patient group, with 9/11 patients having advanced disease at the time of transplant after a median of six earlier treatment regimens. The 2-year OS and PFS for our CTCL patients after reduced-intensity allo-HCT was 45%, despite a median of six earlier regimens per patient. Interestingly enough, the diagnosis of CTCL in our analysis was not associated with a statistically significant difference in OS, PFS, NRM or RR compared with other subtypes of mature T-cell NHL (Figure 2 ). Our observations reiterate the conclusion by Duarte et al. 29 that use of the RIC protocol makes allo-HCT a feasible option, even for these high-risk patients. Performing allo-HCT earlier in the course of the disease, especially for advanced-stage CTCL, might well improve the outcome and quality of life for these patients.
Although the number of patients is insufficient to draw solid conclusions from the univariate and multivariable analyses, the following observations were made. Age X50 years appeared to be associated with improved survival, which may be attributed to confounding factors in this data set, specifically a high proportion of aggressivetype lymphoma in the younger patient group; 5 of 11 patients under 50 years of age had high-grade NK-T lymphoma and one patient had s.c. panniculitis-type lymphoma. In contrast, half the patients older than 50 years had CTCL and only one had high-grade lymphoma. The superior survival for older patients (80% at 2 years, n ¼ 16) underscores that the melphalan/fludarabine regimen is well tolerated by older patients if the disease can be controlled.
The only other factor to have a significant increase in hazard ratio was the presence of grades III-IV aGVHD compared with grades 0-II. Five of thirteen cases of aGVHD were grouped as grade III-IV, and all five of them happened to be grade IV. It is therefore not surprising that these patients with very severe aGVHD should be at higher risk for fatal complications.
The day 100 mortality of 22% (6/27) and NRM rate of 25% at 2 years highlight the need for improved control of infections, GVHD and other complications of allo-HCT. When examined on a case-by-case basis, early NRM appears to correspond to low Karnofsky performance status at the time of transplant, corroborating the role of patient selection in transplant outcomes.
Overall, our results demonstrate that meaningful longterm survival rates and disease control can be achieved even in heavily pretreated mature T-cell lymphoma patients using RIC with melphalan and fludarabine. This retrospective single-institution study is an important addition to the literature supporting the potential for cure of mature T-cell lymphoma patients using RIC allo-HCT. Although the patient population in our report is heterogeneousreflecting the scarcity and diversity of the disease-the standardized conditioning regimen allows a realistic assessment of the efficacy and toxicity of this treatment modality. Because of the rarity of the disease, large multi-center prospective trials would be required to accurately define treatment parameters.
